Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

PILA PHARMA

2.20 SEK-1.79 %9/9 13:37
Less than 1K followers

PILA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
-1.79 %
+71.21 %
+53.31 %
+86.13 %
+6.80 %
-1.79 %
+20.90 %
-73.13 %
-71.84 %

PILA PHARMA is a clinical stage biotechnology company based in Malmö, Sweden. The company is developing novel oral therapeutics for globally common metabolic diseases such as Diabetes, Obesity and Cardiovascular diseases as well as therapeutics for Pain treatment. The company has obtained an orphan drug designation in the United States for the rare disease Erythromelalgia. The company is specializing in development of pharmaceutical drugs based on TRPV1-antagonists.

Read more
Market cap
100.5M SEK
Turnover
315.88K SEK
Revenue
1.13M
EBIT %
-698.23 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
25/2
2027

Annual report '26

20/4
2027

General meeting '27

All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release2026-09-08 16:50

PILA PHARMA: ALL RECENT H1 REPORT AND MANAGEMENT INTERVIEWS NOW ONLINE

PILA PHARMA
Press release2026-09-07 10:43

Analyst Group: Equity Research Report on Pila Pharma - Clinical Phase Begins in Obesity

PILA PHARMA
Press release2026-09-07 10:42

Analyst Group: Aktieanalys på Pila Pharma - Klinisk fas inleds inom obesitas

PILA PHARMA

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-09-01 09:46

BioStock: Pila Pharma takes the next step toward higher doses in PP-CT04 study

PILA PHARMA
Press release2026-09-01 09:46

BioStock: Pila Pharma takes the next step toward higher doses in the PP-CT04 study

PILA PHARMA
Press release2026-08-28 14:25

Vækstaktier.dk: PILA PHARMA reviews an eventful first half, with focus on upcoming obesity trials

PILA PHARMA
Press release2026-08-28 07:37

Carlsquare: Research update Pila Pharma H1 2026: From rat detour to clinical heat

PILA PHARMA
Press release2026-08-27 13:08

Analyst Group: Analyst Group Comment on Pila Pharma’s H1 Report

PILA PHARMA
Press release2026-08-27 13:06

Analyst Group: Analyst Group kommenterar Pila Pharmas H1-rapport

PILA PHARMA
Press release2026-08-27 09:10

PILA PHARMA: INVITATION TO H1 REPORT REVIEW WITH Q&A, TODAY 27 AUGUST AT 11:00 CET

PILA PHARMA
Regulatory press release2026-08-27 08:30

PILA PHARMA PUBLISHES INTERIM REPORT (1 JANUARY – 30 JUNE 2026)

PILA PHARMA
Press release2026-08-19 13:38

BioStock: Regulatoriskt klartecken tar Pila Pharmas obesitaskandidat till mellanfas

PILA PHARMA
Press release2026-08-19 13:38

BioStock: Regulatory green light takes Pila Pharma’s obesity candidate into mid-stage testing

PILA PHARMA
Press release2026-08-19 11:20

Vækstaktier.dk: PILA PHARMA receives regulatory approval for important clinical trial in people with obesity

PILA PHARMA
Press release2026-08-18 17:19

Analyst Group: Analyst Group Comment on Pila Pharma's Regulatory Approval to Conduct a Clinical Study in Obesity

PILA PHARMA
Press release2026-08-18 17:19

Analyst Group: Analyst Group kommenterar att Pila Pharma har erhållit godkännande att genomföra en klinisk studie inom obesitas

PILA PHARMA
Press release2026-08-18 15:55

Carlsquare: Mrkt BUZZ Pila Pharma: Receives go-ahead for start of obesity trials

PILA PHARMA
Regulatory press release2026-08-18 11:30

PILA PHARMA: REGULATORY APPROVAL RECEIVED TO CONDUCT PP-CT04, A 12-WEEK TRIAL EXPLORING THE SAFETY AND EFFICACY OF XEN-D0501 IN PEOPLE LIVING WITH OBESITY

PILA PHARMA
Press release2026-07-31 11:15

PILA PHARMA: CHAIRMAN DORTE X. GRAM REPORT SALE/PURCHASE TRANSACTION BETWEEN OWN CONTROLLED COMPANIES

PILA PHARMA
Press release2026-06-03 13:50

Carlsquare: Equity reseach Pila Pharma: Sizing up a small molecule in obesity

PILA PHARMA